FXR signaling in metabolic disease.
Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, has been shown to be important in controlling numerous metabolic pathways; these include roles in maintaining bile acid, lipid and glucose homeostasis, in preventing intestinal bacterial infection and gallstone formation and in modulating liver regeneration and tumorigenesis. The accumulating data suggest that FXR may be a pharmaceutical target for the treatment of certain metabolic diseases.
Zhang
Yanqiao
Y
Department of Biological Chemistry, University of California at Los Angeles, 47-105 CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA. yqzhang@mednet.ucla.edu
Edwards
Peter A
PA
D001419:Bacteria / Q000254:growth & development; D001647:Bile Acids and Salts / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism* / Q000502:physiology; D005947:Glucose / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism; D008113:Liver Neoplasms / Q000503:physiopathology; D008115:Liver Regeneration; D008659:Metabolic Diseases / Q000378:metabolism*; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism* / Q000502:physiology; D015398:Signal Transduction; D014157:Transcription Factors / Q000378:metabolism* / Q000502:physiology; D000099150:Receptor, Farnesoid X-Activated
D001647:Bile Acids and Salts; D004268:DNA-Binding Proteins; D005947:Glucose; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D000099150:Receptor, Farnesoid X-Activated